DOCSLIB.ORG

September, 2010

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

NIDA - Director's Report - September, 2010 NIDA Home > Publications > Director's Reports Director's Report to the National Advisory Council on Drug Abuse - September, 2010 Report Index Index Report for September, 2010 Research Findings Report for May, 2010 Basic Neurosciences Research Report for February, 2010 Basic Behavioral Research Older Reports - go to the Archives Behavioral and Brain Development Research Clinical Neuroscience Research Epidemiology and Etiology Research Prevention Research NACDA Behavioral and Integrative Treatment Research Legislation Research on Pharmacotherapies for Drug Abuse Research on Medical Consequences of Drug Abuse and Co-Occurring Infections (HIV/AIDS, HCV) Services Research Clinical Trials Network Research Intramural Research Program Activities Extramural Policy and Review Activities Congressional Affairs International Activities Meetings and Conferences Media and Education Activities Planned Meetings Publications Staff Highlights Grantee Honors https://archives.drugabuse.gov/DirReports/DirRep910/[11/17/16, 11:34:51 PM] NIDA - Director's Report - September, 2010 Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? _ See our Contact Information. https://archives.drugabuse.gov/DirReports/DirRep910/[11/17/16, 11:34:51 PM] NIDA - Director's Report - September, 2010 NIDA Home > Publications > Director's Reports Director's Report to the National Advisory Council on Drug Abuse - September, 2010 Report Index Index Report for September, 2010 Research Findings Report for May, 2010 Basic Neurosciences Research Report for February, 2010 Basic Behavioral Research Older Reports - go to the Archives Behavioral and Brain Development Research Clinical Neuroscience Research Epidemiology and Etiology Research Prevention Research NACDA Behavioral and Integrative Treatment Research Legislation Research on Pharmacotherapies for Drug Abuse Research on Medical Consequences of Drug Abuse and Co-Occurring Infections (HIV/AIDS, HCV) Services Research Clinical Trials Network Research Intramural Research Program Activities Extramural Policy and Review Activities Congressional Affairs International Activities Meetings and Conferences Media and Education Activities Planned Meetings Publications Staff Highlights Grantee Honors https://archives.drugabuse.gov/DirReports/DirRep910/default.html[11/17/16, 11:34:56 PM] NIDA - Director's Report - September, 2010 Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? _ See our Contact Information. https://archives.drugabuse.gov/DirReports/DirRep910/default.html[11/17/16, 11:34:56 PM] NIDA - Director's Report - September, 2010 NIDA Home > Publications > Director's Reports > September, 2010 Index Director's Report to the National Advisory Council on Drug Abuse - September, 2010 Index Research Findings - Basic Neuroscience Research Research Findings RGS9-2 Signaling Partners Basic Neurosciences Research Regulators of G protein signaling (RGS) are known to bind to G alpha proteins, Basic Behavioral Research speeding the process of GTP hydrolysis and terminating the signaling pathway in which the GPCR participates. Based on immunoblotting and Behavioral and Brain immunoprecipitation results, the RGS9-2 protein, highly expressed in the Development Research striatum and nucleus accumbens, forms a tertiary complex with the G protein Clinical Neuroscience Gbeta5, and with R7BP (R7 binding protein) at distinct binding regions of Research RGS9-2. Certain details about the stoichiometry of this complex are Epidemiology and Etiology understood: Gbeta5 is necessary for the constitutive expression of RGS9-2, Research and these two partners are expressed in direct proportion, i.e., both their expression levels increase, or decrease together, as in the case of R7BP being Prevention Research absent in a R7BP knockout mouse species. The binding of R7BP may aid in Behavioral and Integrative targeting RGS9-2 to post-synaptic neuronal regions, and may also contribute to Treatment Research the stability of the RGS9-2/Gbeta5 complex. RGS9-2 has been studied as a Research on regulator of dopamine and opioid (mu receptor) signaling in the animal brain. Pharmacotherapies for Drug RGS9-2 levels are decreased in rats chronically self-administering cocaine, and Abuse RGS9-2 knockout mice have increased sensitivity to the rewards of morphine (lower doses) in place conditioning experiments, compared to wild type mice. Research on Medical RGS9-2 knockout mice show enhanced withdrawal symptoms following Consequences of Drug morphine administration. Dr. Martemyanov and his associates at the University Abuse and Co-Occurring of Minnesota have carried out a quantitative proteomics study to detect Infections (HIV/AIDS, HCV) changes in the proteins that complex to RGS9-2 when R7BP is absent, using Services Research the R7BP knockout mouse. Three striatal brain samples were used: a wild type, Clinical Trials Network an R7BP knockout sample, and, for control purposes, an RGS9-2 knockout Research sample to detect non-specific interactions in the absence of RGS9-2. Following Intramural Research immunoprecipitation to obtain proteins from the samples, each sample was treated with trypsin to produce fragment peptides, which were derivatized with Program Activities three different isotopically-labeled tags, samples were combined, separated by LC, and analyzed by mass spectrometry. RGS9-2 interaction with Gbeta5 was Extramural Policy and confirmed, and, in the absence of R7BP in the complex, twenty-one new Review Activities binding partners of RGS9-2 were identified as being upregulated, including the heat shock chaperone protein Hsc70. Hsc70 was absent (no Congressional Affairs immunoprecipitation) in RGS9-2 knockout samples, and in R7BP knockout striatal tissue, increasing in amount when R7BP was absent. The binding of International Activities Hsc70 protein was found to take place at a C-terminus peptide fragment of RGS9-2. When Hsc70 was "silenced" by siRNA for Hsc70, the RGS9-2 Meetings and Conferences expression increased 17%, based on Western blotting analysis. Therefore, Hsc70 negatively regulated the RGS9-2 expression. Although the mechanism of Media and Education Hsc70 action is not known presently, Hsc70 may serve to regulate RGS9-2 by Activities targeting a RGS9-2 complex into lysosomes, where it can be degraded. Posokhova E, Uversky V, Martemyanov KA. Proteomic identification of Hsc70 as Planned Meetings a mediator of RGS9-2 degradation by in vivo interactome analysis. J Proteome https://archives.drugabuse.gov/DirReports/DirRep910/DirectorReport1.html[11/17/16, 11:35:00 PM] NIDA - Director's Report - September, 2010 Res 2010; 9(3): 1510-1521. Publications Negative Allosteric Modulators that Target Human α4β2 Neuronal Staff Highlights Nicotinic Receptors Grantee Honors Allosteric modulation of nicotinic acetylcholine receptors (nAChRs) is considered to be one of the most promising approaches for therapeutics. The present authors previously reported on the pharmacological activity of several compounds that acted as negative allosteric modulators (NAMs) of nAChRs. In this publication the effects of 30 NAMs from the authors' small chemical library on both human α4β2 (Hα4β2) nAChRs and human α3β4 (Hα3β4) nAChRs expressed in HEK ts201 cells were investigated. Using calcium accumulation assays, these NAMs inhibited nAChRs activation with IC50 values ranging from 2.4 µM to greater than 100 µM. Several NAMs showed relative selectivity for Hα4β2 nAChRs with IC50 values in the low micromolar range. A lead molecule, KAB-18 was identified that showed relative selectivity for Hα4β2 nAChRs. This molecule contains 3-phenyl rings, 1 piperidine ring, and 1 ester bond linkage. Structure-activity relationship (SAR) analyses revealed 3 regions of KAB-18 that contributed to its relative selectivity. Predictive 3D-QSAR (comparative molecular field analysis and comparative molecular similarity indices analysis) models were generated from these data and a pharmacophore model was constructed to determine the chemical features that were important for biological activity. Using docking approaches and molecular dynamics on Hα4β2 nAChR homology model, a binding mode for KAB-18 at the α/β sub-unit interface that corresponded to the predicted pharmacophore was described. This binding study was supported by mutagenesis studies. In summary, these studies highlight the importance of SAR, computational, and molecular biology approaches for the design and synthesis of potent and selective antagonists targeting specific nAChR sub-types. Henderson BJ, Pavlovicz RE, Allen JD, Gonzalez-Cestari TF, Orac CM, Bonnell AB, Zhu MX, Thomas Boyd R, Li C, Bergmeier SC, McKay DB. Negative Allosteric Modulators that Target Human α4β2 Neuronal Nicotinic Receptors, J Pharmacol Exp Ther. 2010, Jun 15. [Epub ahead of print]. Molecular Mechanisms Involving Cocaine/Sigma Receptor- Mediated Induction of MCP-1: Implication For Increased Monocyte Transmigration Cocaine abuse hastens the neurodegeneration often associated with advanced HIV-1infection. The mechanisms, in part, revolve around the neuroinflammatory processes mediated by the chemokine monocyte chemotactic protein-1 (MCP-1/CCL2).
Recommended publications
  • INVESTIGATION of NATURAL PRODUCT SCAFFOLDS for the DEVELOPMENT of OPIOID RECEPTOR LIGANDS by Katherine M

    INVESTIGATION of NATURAL PRODUCT SCAFFOLDS for the DEVELOPMENT of OPIOID RECEPTOR LIGANDS by Katherine M

    INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS By Katherine M. Prevatt-Smith Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. _________________________________ Chairperson: Dr. Thomas E. Prisinzano _________________________________ Dr. Brian S. J. Blagg _________________________________ Dr. Michael F. Rafferty _________________________________ Dr. Paul R. Hanson _________________________________ Dr. Susan M. Lunte Date Defended: July 18, 2012 The Dissertation Committee for Katherine M. Prevatt-Smith certifies that this is the approved version of the following dissertation: INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS _________________________________ Chairperson: Dr. Thomas E. Prisinzano Date approved: July 18, 2012 ii ABSTRACT Kappa opioid (KOP) receptors have been suggested as an alternative target to the mu opioid (MOP) receptor for the treatment of pain because KOP activation is associated with fewer negative side-effects (respiratory depression, constipation, tolerance, and dependence). The KOP receptor has also been implicated in several abuse-related effects in the central nervous system (CNS). KOP ligands have been investigated as pharmacotherapies for drug abuse; KOP agonists have been shown to modulate dopamine concentrations in the CNS as well as attenuate the self-administration of cocaine in a variety of species, and KOP antagonists have potential in the treatment of relapse. One drawback of current opioid ligand investigation is that many compounds are based on the morphine scaffold and thus have similar properties, both positive and negative, to the parent molecule. Thus there is increasing need to discover new chemical scaffolds with opioid receptor activity.
  • The Cross-Talk of HIV-1 Tat and Methamphetamine in HIV-Associated Neurocognitive Disorders

    The Cross-Talk of HIV-1 Tat and Methamphetamine in HIV-Associated Neurocognitive Disorders

    REVIEW published: 23 October 2015 doi: 10.3389/fmicb.2015.01164 The cross-talk of HIV-1 Tat and methamphetamine in HIV-associated neurocognitive disorders Sonia Mediouni 1, Maria Cecilia Garibaldi Marcondes 2, Courtney Miller 3,4, Jay P. McLaughlin 5 and Susana T. Valente 1* 1 Department of Infectious Diseases, The Scripps Research Institute, Jupiter, FL, USA, 2 Department of Molecular and Cellular Neurosciences, The Scripps Research Institute, La Jolla, CA, USA, 3 Department of Metabolism and Aging, The Scripps Research Institute, Jupiter, FL, USA, 4 Department of Neuroscience, The Scripps Research Institute, Jupiter, FL, USA, 5 Department of Pharmacodynamics, University of Florida, Gainesville, FL, USA Antiretroviral therapy has dramatically improved the lives of human immunodeficiency virus 1 (HIV-1) infected individuals. Nonetheless, HIV-associated neurocognitive disorders (HAND), which range from undetectable neurocognitive impairments to severe dementia, still affect approximately 50% of the infected population, hampering their quality of life. The persistence of HAND is promoted by several factors, including longer life expectancies, Edited by: the residual levels of virus in the central nervous system (CNS) and the continued Venkata S. R. Atluri, presence of HIV-1 regulatory proteins such as the transactivator of transcription (Tat) Florida International University, USA Reviewed by: in the brain. Tat is a secreted viral protein that crosses the blood–brain barrier into the Masanori Baba, CNS, where it has the ability to directly act on neurons and non-neuronal cells alike. Kagoshima University, Japan These actions result in the release of soluble factors involved in inflammation, oxidative Shilpa J. Buch, University of Nebraska Medical stress and excitotoxicity, ultimately resulting in neuronal damage.
  • Current Awareness in Clinical Toxicology Editors: Damian Ballam Msc and Allister Vale MD

    Current Awareness in Clinical Toxicology Editors: Damian Ballam Msc and Allister Vale MD

    Current Awareness in Clinical Toxicology Editors: Damian Ballam MSc and Allister Vale MD February 2016 CONTENTS General Toxicology 9 Metals 38 Management 21 Pesticides 41 Drugs 23 Chemical Warfare 42 Chemical Incidents & 32 Plants 43 Pollution Chemicals 33 Animals 43 CURRENT AWARENESS PAPERS OF THE MONTH How toxic is ibogaine? Litjens RPW, Brunt TM. Clin Toxicol 2016; online early: doi: 10.3109/15563650.2016.1138226: Context Ibogaine is a psychoactive indole alkaloid found in the African rainforest shrub Tabernanthe Iboga. It is unlicensed but used in the treatment of drug and alcohol addiction. However, reports of ibogaine's toxicity are cause for concern. Objectives To review ibogaine's pharmacokinetics and pharmacodynamics, mechanisms of action and reported toxicity. Methods A search of the literature available on PubMed was done, using the keywords "ibogaine" and "noribogaine". The search criteria were "mechanism of action", "pharmacokinetics", "pharmacodynamics", "neurotransmitters", "toxicology", "toxicity", "cardiac", "neurotoxic", "human data", "animal data", "addiction", "anti-addictive", "withdrawal", "death" and "fatalities". The searches identified 382 unique references, of which 156 involved human data. Further research revealed 14 detailed toxicological case reports. Current Awareness in Clinical Toxicology is produced monthly for the American Academy of Clinical Toxicology by the Birmingham Unit of the UK National Poisons Information Service, with contributions from the Cardiff, Edinburgh, and Newcastle Units. The NPIS is commissioned by Public Health England Current Awareness in Clinical Toxicology Editors: Damian Ballam MSc and Allister Vale MD February 2016 Current Awareness in Clinical Toxicology is produced monthly for the American Academy of Clinical Toxicology by the Birmingham Unit of the UK National Poisons Information Service, with contributions from the Cardiff, Edinburgh, and Newcastle Units.
  • (19) United States (12) Patent Application Publication (10) Pub

    (19) United States (12) Patent Application Publication (10) Pub

    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs

    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs

    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
  • Assessment of Insecticidal Activity of Benzylisoquinoline Alkaloids From

    Assessment of Insecticidal Activity of Benzylisoquinoline Alkaloids From

    molecules Article Assessment of Insecticidal Activity of Benzylisoquinoline Alkaloids from Chilean Rhamnaceae Plants against Fruit-Fly Drosophila melanogaster and the Lepidopteran Crop Pest Cydia pomonella Soledad Quiroz-Carreño 1, Edgar Pastene-Navarrete 1 , Cesar Espinoza-Pinochet 2, Evelyn Muñoz-Núñez 1, Luis Devotto-Moreno 3, Carlos L. Céspedes-Acuña 1 and Julio Alarcón-Enos 1,* 1 Laboratorio de Síntesis y Biotransformación de Productos Naturales, Dpto. Ciencias Básicas, Universidad del Bio-Bio, PC3780000 Chillán, Chile; [email protected] (S.Q.-C.); [email protected] (E.P.-N.); [email protected] (E.M.-N.); [email protected] (C.L.C.-A.) 2 Dpto. Agroindustria, Facultad de Ingeniería Agrícola, Universidad de Concepción, 3780000 Chillán, Chile; [email protected] 3 Instituto de Investigaciones Agropecuarias, INIA Quilamapu, 3780000 Chillán, Chile; [email protected] * Correspondence: [email protected] Academic Editors: Daniel Granato and Petri Kilpeläinen Received: 29 September 2020; Accepted: 27 October 2020; Published: 3 November 2020 Abstract: The Chilean plants Discaria chacaye, Talguenea quinquenervia (Rhamnaceae), Peumus boldus (Monimiaceae), and Cryptocarya alba (Lauraceae) were evaluated against Codling moth: Cydia pomonella L. (Lepidoptera: Tortricidae) and fruit fly Drosophila melanogaster (Diptera: Drosophilidae), which is one of the most widespread and destructive primary pests of Prunus (plums, cherries, peaches, nectarines, apricots, almonds), pear, walnuts, and chestnuts, among other. Four benzylisoquinoline alkaloids (coclaurine, laurolitsine, boldine, and pukateine) were isolated from the above mentioned plant species and evaluated regarding their insecticidal activity against the codling moth and fruit fly. The results showed that these alkaloids possess acute and chronic insecticidal effects. The most relevant effect was observed at 10 µg/mL against D.
  • Effect of Repeated MDMA Exposure on Rat Brain and Behaviour

    Effect of Repeated MDMA Exposure on Rat Brain and Behaviour

    Effect of repeated MDMA exposure on rat brain and behaviour by Ross van de Wetering A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy Victoria University of Wellington, New Zealand 2020 Table of contents Absract ........................................................................................................................... 5 List of abbreviations ...................................................................................................... 7 CHAPTER 1: GENERAL INTRODUCTION ............................................................ 10 Introduction ........................................................................................................................ 10 Behavioural fundamentals of addiction ........................................................................... 12 Studying addiction ........................................................................................................... 13 Self-administration. ...................................................................................................... 14 Behavioural sensitisation. ............................................................................................ 18 Neurocircuitry of addiction ............................................................................................... 20 Ventral tegmental area and nucleus accumbens .............................................................. 20 Dopamine and reinforcement. .....................................................................................
  • Biased Signaling by Endogenous Opioid Peptides

    Biased Signaling by Endogenous Opioid Peptides

    Biased signaling by endogenous opioid peptides Ivone Gomesa, Salvador Sierrab,1, Lindsay Lueptowc,1, Achla Guptaa,1, Shawn Goutyd, Elyssa B. Margolise, Brian M. Coxd, and Lakshmi A. Devia,2 aDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029; bDepartment of Physiology & Biophysics, Virginia Commonwealth University, Richmond, VA 23298; cSemel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA 90095; dDepartment of Pharmacology & Molecular Therapeutics, Uniformed Services University, Bethesda MD 20814; and eDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA 94143 Edited by Susan G. Amara, National Institutes of Health, Bethesda, MD, and approved April 14, 2020 (received for review January 20, 2020) Opioids, such as morphine and fentanyl, are widely used for the possibility that endogenous opioid peptides could vary in this treatment of severe pain; however, prolonged treatment with manner as well (13). these drugs leads to the development of tolerance and can lead to For opioid receptors, studies showed that mice lacking opioid use disorder. The “Opioid Epidemic” has generated a drive β-arrestin2 exhibited enhanced and prolonged morphine-mediated for a deeper understanding of the fundamental signaling mecha- antinociception, and a reduction in side-effects, such as devel- nisms of opioid receptors. It is generally thought that the three opment of tolerance and acute constipation (15, 16). This led to types of opioid receptors (μ, δ, κ) are activated by endogenous studies examining whether μOR agonists exhibit biased signaling peptides derived from three different precursors: Proopiomelano- (17–20), and to the identification of agonists that preferentially cortin, proenkephalin, and prodynorphin.
  • BBC Program 2016.Pages

    BBC Program 2016.Pages

    March 5-6, 2016 La Quinta Inn & Suites Medical Center San Antonio, TX Behavior, Biology, and Chemistry: Translational Research in Addiction BBC 2016 BBC Publications BBC 2011 Stockton Jr SD and Devi LA (2012) Functional relevance of μ–δ opioid receptor heteromerization: A Role in novel signaling and implications for the treatment of addiction disorders: From a symposium on new concepts in mu-opioid pharmacology. Drug and Alcohol Dependence Mar 1;121(3):167-72. doi: 10.1016/j.drugalcdep.2011.10.025. Epub 2011 Nov 23 Traynor J (2012) μ-Opioid receptors and regulators of G protein signaling (RGS) proteins: From a sym- posium on new concepts in mu-opioid pharmacology. Drug and Alcohol Dependence Mar 1;121(3): 173-80. doi: 10.1016/j.drugalcdep.2011.10.027. Epub 2011 Nov 29 Lamb K, Tidgewell K, Simpson DS, Bohn LM and Prisinzano TE (2012) Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: New concepts in mu opioid receptor pharmacology: From a symposium on new concepts in mu-opioid pharma- cology. Drug and Alcohol Dependence Mar 1;121(3):181-8. doi: 10.1016/j.drugalcdep.2011.10.026. Epub 2011 Nov 26 Whistler JL (2012) Examining the role of mu opioid receptor endocytosis in the beneficial and side-ef- fects of prolonged opioid use: From a symposium on new concepts in mu-opioid pharmacology. Drug and Alcohol Dependence Mar 1;121(3):189-204. doi: 10.1016/j.drugalcdep.2011.10.031. Epub 2012 Jan 9 BBC 2012 Zorrilla EP, Heilig M, de Wit, H and Shaham Y (2013) Behavioral, biological, and chemical perspectives on targeting CRF1 receptor antagonists to treat alcoholism.
  • Neuropharmacology and Toxicology of Novel Amphetamine-Type Stimulants

    Neuropharmacology and Toxicology of Novel Amphetamine-Type Stimulants

    Neuropharmacology and toxicology of novel amphetamine-type stimulants Bjørnar den Hollander Institute of Biomedicine, Pharmacology University of Helsinki Academic Dissertation To be presented, with the permission of the Medical Faculty of the University of Helsinki, for public examination in lecture hall 2, Biomedicum Helsinki 1, Haartmaninkatu 8, on January 16th 2015 at 10 am. Helsinki 2015 Supervisors Thesis committee Esa R. Korpi, MD, PhD Eero Castrén, MD, PhD Institute of Biomedicine, Pharmacology Neuroscience Center Faculty of Medicine University of Helsinki P.O. Box 63 (Haartmaninkatu 8) P.O. Box 56 (Viikinkaari 4) 00014 University of Helsinki, Finland 00014 University of Helsinki, Finland Esko Kankuri, MD, PhD Sari Lauri, PhD Institute of Biomedicine, Pharmacology Neuroscience Center and Faculty of Medicine Department of Biosciences/ Physiology P.O. Box 63 (Haartmaninkatu 8) University of Helsinki 00014 University of Helsinki, Finland P.O.Box 65 (Viikinkaari 1) 00014 University of Helsinki, Finland Reviewers Dissertation opponent Atso Raasmaja, Professor, PhD Prof David Nutt DM FRCP FRCPsych Division of Pharmacology and FMedSci Pharmacotherapy Edmond J. Safra Chair of Faculty of Pharmacy Neuropsychopharmacology P. O. Box 56 (Viikinkaari 5E) Division of Brain Sciences 00014 University of Helsinki, Finland Dept of Medicine Imperial College London Petri J. Vainio, MD, PhD Burlington Danes Building Pharmacology, Drug Development and Hammersmith Hospital Therapeutics Du Cane Road Institute of Biomedicine London W12 0NN, United Kingdom Faculty of Medicine Kiinamyllynkatu 10 C 20014 University of Turku, Finland The cover layout is done by Anita Tienhaara. The cover photo is by Edd Westmacott and shows a close-up of ecstasy tablets, photographed in Amsterdam in 2004.
  • Differential Regulation of Serotonin 2A Receptor Responsiveness by Agonist

    Differential Regulation of Serotonin 2A Receptor Responsiveness by Agonist

    Differential regulation of serotonin 2A receptor responsiveness by agonist- directed interactions with arrestin2 DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Cullen Laura Schmid, B.S. Neuroscience Graduate Studies Program The Ohio State University 2011 Dissertation Committee: Laura M. Bohn, Co-advisor Georgia A. Bishop, Co-advisor Candice C. Askwith Wolfgang Sadee Copyright by Cullen Laura Schmid 2011 Abstract The G protein-coupled, serotonin 2A (5-HT2A) receptor is a major drug target for the treatment of a number of mental health disorders, including schizophrenia, anxiety and depression. In addition to modulating several of the physiological effects of the neurotransmitter serotonin, activation of the 5-HT2A receptor mediates the psychotomimetic effects of serotonergic hallucinogenic drugs, such as lysergic acid diethylamide (LSD), 2,5-dimethoxy-4-iodoamphetamine (DOI) and 5-methoxy-N,N- dimethyltryptamine (5-MeO-DMT). Though hallucinogens are agonists at the 5-HT2A receptor, not all 5-HT2A receptor agonists induce hallucinations in humans, including the endogenous ligand serotonin. Therefore, the activation of the 5-HT2A receptor can result in different biological responses depending upon the chemical nature of the ligand, a concept that has been referred to as “functional selectivity.” One way in which ligands can induce differential signaling at GPCRs is through interactions with arrestins, which can act to dampen or facilitate receptor signaling cascades or mediate the internalization of receptors into intracellular vesicles. The overarching hypothesis of this dissertation is that the interaction between the regulatory protein, arrestin2, and the 5-HT2A receptor is a critical point in the divergence of agonist-directed 5-HT2A receptor responsiveness.
  • Potentiation of Yohimbine-Induced Lethality in Mice: Predictor of Antidepressant Potential

    Potentiation of Yohimbine-Induced Lethality in Mice: Predictor of Antidepressant Potential

    Drug Development Research 3:357-363 (1983) Potentiation of Yohimbine-Induced Lethality in Mice: Predictor of Antidepressant Potential Jeffrey B. Malick Biomedical Research Department, Stuart Pharmaceuticals, Division of ICI Americas, Inc., Wilmington, Delaware ABSTRACT Malick, J.B.: Potentiation of yohimbine-induced lethality in mice: Predictor of antidepres- sant potential. Drug Dev. Res. 3:357-363, 1983. The ability of antidepressant agents to potentiate the lethal or toxic effects of yohimbine in mice was evaluated. With very few exceptions, the antidepressants were the only agents that significantly enhanced yohimbine-induced lethality. All of the clinically effective anti- depressants, both typical (e.g., amine reuptake inhibitors, monoamine oxidase inhibitors) and atypical (e.g., mianserin, iprindole, bupropion, quipazine) drugs, produced a dose- related potentiation of yohimbine in mice. Representative anxiolytics and antipsychotics failed to potentiate yohimbine over a wide range of doses. Although several possible “false positives” (e.g., atropine, chlorpheniramine, and d-amphetamine) would be detected in this procedure, these same agents would be detected in other models (e.g., tetrabenazine antagonism, behavioral despair) considered predictive of antidepressant potential. Thus, the potentiation of yohimbine-induced lethality test in mice appears to represent a useful screening procedure for discovering potential antidepressant drugs. Key words: yohimbine, antidepressants, potentiation INTRODUCTION Antidepressants potentiate